Entero Therapeutics (NASDAQ:GRDX – Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday, Wall Street Zen reports.
Entero Therapeutics Trading Down 5.9%
Shares of GRDX stock opened at $3.25 on Friday. The business’s 50 day moving average price is $4.29 and its 200-day moving average price is $3.61. Entero Therapeutics has a fifty-two week low of $1.87 and a fifty-two week high of $6.93.
Entero Therapeutics (NASDAQ:GRDX – Get Free Report) last released its quarterly earnings results on Monday, November 16th. The company reported ($0.27) earnings per share for the quarter. The company had revenue of $0.04 million for the quarter.
About Entero Therapeutics
Entero Therapeutics is a clinical-stage biopharmaceutical company developing treatments for gastrointestinal diseases. Its research has focused on therapies designed to act in the digestive tract, including candidates for celiac disease, inflammatory bowel disease and exocrine pancreatic insufficiency. Its pipeline has included latiglutenase, an oral enzyme therapy intended to break down gluten in the gut, and adrulipase, an oral enzyme replacement candidate for people with exocrine pancreatic insufficiency.
Recommended Stories
- Five stocks we like better than Entero Therapeutics
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Entero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
